Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes

Diabetologia

Volumn 58, Issue 6, 2015, Pages 1363-1371

  Looker, Helen C ^{a,b,c,d,e,f,g,h,i,j,k}   Colombo, Marco ^{a,b,c,d,e,f,g,h,i,j,k}   Agakov, Felix ^{a,b,c,d,e,f,g,h,i,j,k}   Zeller, Tanja ^{a,b,c,d,e,f,g,h,i,j,k}   Groop, Leif ^{a,b,c,d,e,f,g,h,i,j,k}   Thorand, Barbara ^{a,b,c,d,e,f,g,h,i,j,k}   Palmer, Colin N ^{a,b,c,d,e,f,g,h,i,j,k}   Hamsten, Anders ^{a,b,c,d,e,f,g,h,i,j,k}   de Faire, Ulf ^{a,b,c,d,e,f,g,h,i,j,k}   Nogoceke, Everson ^{a,b,c,d,e,f,g,h,i,j,k}   Livingstone, Shona J ^{a,b,c,d,e,f,g,h,i,j,k}   Salomaa, Veikko ^{a,b,c,d,e,f,g,h,i,j,k}   Leander, Karin ^{a,b,c,d,e,f,g,h,i,j,k}   Barbarini, Nicola ^{a,b,c,d,e,f,g,h,i,j,k}   Bellazzi, Riccardo ^{a,b,c,d,e,f,g,h,i,j,k}   van Zuydam, Natalie ^{a,b,c,d,e,f,g,h,i,j,k}   McKeigue, Paul M ^{a,b,c,d,e,f,g,h,i,j,k}   Colhoun, Helen M ^{a,b,c,d,e,f,g,h,i,j,k}  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c PHARMATICS LIMITED   (United Kingdom)

^d UNIVERSITY HEART CENTER HAMBURG   (Germany)

^e LUND UNIVERSITY   (Sweden)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g KAROLINSKA INSTITUTE   (Sweden)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^j UNIVERSITY OF PAVIA   (Italy)

^k NHS FIFE   (United Kingdom)

more..

Author keywords

Cardiovascular diseases; Epidemiology; Protein biomarkers; Risk factors; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN C3; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; INTERLEUKIN 15; INTERLEUKIN 6; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN T;

AGED; AREA UNDER THE CURVE; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; STATISTICAL MODEL;

AGED; APOLIPOPROTEIN C-III; AREA UNDER CURVE; BIOMARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTERLEUKIN-15; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; ROC CURVE; TROPONIN T;

EID: 84939940579     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3535-6     Document Type: Article

References (37)

1. U.S. Food and Drug Administration (2008) Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. U.S. Food and Drug Administration, Silver Spring
2. Innovative Medicines Initiative (2010) Summit. Available from www.imi.europa.eu/content/summit. Accessed 30 Oct 2014
3. Pearson ER, Donnelly LA, Kimber C et al (2011) Variation in TCF7l2 influences therapeutic response to sulfonylureas—a GoDARTs study. Diabetes 56:2178–2182
4. Ahluwalia TS, Lindholm E, Groop LC (2011) Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 54:2295–2302
5. Malarstig A, Silveira A, Wagsater D et al (2011) Plasma CD93 concentration is a potential novel biomarker for coronary artery disease. J Intern Med 270:229–236
6. Baldassarre D, Nyyssönen K, Rauramaa R et al (2010) Cross-sectional analysis of baseline data to identify the major determinants of carotid intima–media thickness in a European population: the IMPROVE study. Eur Heart J 31:614–622
7. Thorand B, Kolb H, Baumert J et al (2005) Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002. Diabetes 54:2932–2938
8. Nuzzo A, Mulas F, Gabetta M et al (2010) Text mining approaches for automated literature knowledge extraction and representation. Stud Health Technol Inform 160:954–958
9. Hiukka A, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR (2005) Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 48:1207–1215
10. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P (2000) Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 43:703–708
11. Myriad RBM (2011) HumanMAPs. Available from https://rbm.myriad.com/products-services/humanmap-services/. Accessed 30 Oct 2014
12. D’Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753
13. Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101:671–679
14. R Development Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
15. Chen SSB, Gopinath RA (2001) Gaussianization. Adv Neural Inf Process Syst 13:423–429
16. Tibshirani R (1996) Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B Methodol 58:267–288
17. Bansal A, Pepe MS (2013) Estimating improvement in prediction with matched case-control designs. Lifetime Data Anal 19:170–201
18. Battistoni A, Rubattu S, Volpe M (2012) Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol 157:160–168
19. Saunders JT, Nambi V, de Lemos JA et al (2011) Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 123:1367–1376
20. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ (1989) Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 264:16339–16342
21. Chan DC, Chen MM, Ooi EM, Watts GF (2008) An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 62:799–809
22. Caron S, Verrijken A, Mertens I et al (2011) Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 31:513–519
23. Hiukka A, Stahlman M, Pettersson C et al (2009) ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 58:2018–2026
24. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM (2011) Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 124:2065–2072
25. Scheffer PG, Teerlink T, Dekker JM et al (2008) Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem 54:1325–1330
26. Tentolouris N, Stylianou A, Lourida E et al (2007) High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res 48:218–225
27. Roselli della Rovere G, Lapolla A, Sartore G et al (2003) Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis 13:46–51
28. Gokkusu C, Aydin M, Ozkok E et al (2010) Influences of genetic variants in interleukin-15 gene and serum interleukin-15 levels on coronary heart disease. Cytokine 49:58–63
29. van Es T, van Puijvelde GH, Michon IN et al (2011) IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice. Vaccine 29:976–983
30. Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R (2012) Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS ONE 7:e34218
31. Colhoun HM, Betteridge DJ, Durrington P et al (2011) Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 60:2379–2385
32. de Kleijn DP, Moll FL, Hellings WE et al (2010) Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 30:612–619
33. Bleijerveld OB, Zhang YN, Beldar S et al (2013) Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis. Proteomics Clin Appl 7:490–503
34. Kristensen LP, Larsen MR, Mickley H et al (2014) Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. J Proteome 101:141–153
35. van Dieren S, Beulens JW, Kengne AP et al (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98:360–369
36. Kengne AP, Patel A, Marre M et al (2011) Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 18:393–398
37. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31:2038–2043